Volume 8, Issue 3 (September 2016)                   Iranian Journal of Blood and Cancer 2016, 8(3): 75-79 | Back to browse issues page

XML Print


1- , sadeghi_mbrc@yahoo.com
Abstract:   (5399 Views)

Background: The oncologic behavior of mucinous adenocarcinoma (MA) of colorectal differs from non-mucinous adenocarcinoma (NMA). MA is more advanced at diagnosis and has a poorer prognosis than NMA. We aimed to evaluate prognostic factors and survival rate in patients with MA compared with NMA in Western Iran.
Methods: During 2008-2015 in a retrospective study, 83 patients with CRC referred to the Oncology Clinic in Kermanshah, Iran. Binary logistic regression analysis was used for the correlation between risk variables with the type of pathology.
Results: The mean follow-up was 32 months (range, 12-72 months) and in this interval, there were 26 deaths and 3 patients were lost to follow-up and therefore, were omitted them from survival analysis. There was no significant correlation between NMA and MA with sex, degree of differentiation of tumor, tumor site, tumor size, KRAS mutation and lymph node metastasis, but a significant correlation was observed with age (P<0.05). Binary logistic regression analysis showed there was a significant correlation between age (P=0.01, odds ratio 11.93 and 95% CI 1.61-88.46) and type of pathology. The survival rate and mean survival were 54.3% and 23 months for NMA group, versus 80.6% and 25.4 months for MA group, respectively.
Conclusion: The prevalence of NMA in CRC was more than MA. In this study, the MA patients had lower age and more risk of recurrence compared to NMA patients and unlike other studies, 5-year survival rate was significantly higher in NMA patients than that in MA patients.

Full-Text [PDF 733 kb]   (1959 Downloads)    
: Original Article | Subject: Adults Hematology & Oncology
Received: 2016/02/21 | Accepted: 2016/10/18 | Published: 2016/10/18

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.